Anticancer Role of MUC1 Aptamer-miR-29b Chimera in Epithelial Ovarian Carcinoma Cells Through Regulation of PTEN Methylation

Overview

Journal Target Oncol

Specialty Oncology

Date 2012 Nov 27

PMID 23179556

Citations 44

Authors

Furong Dai

Yi Zhang

Xin Zhu

Nianchun Shan

Yuxiang Chen

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer has a poor prognosis and advanced ovarian cancer lacks effective therapy. In this study, we seek to establish targeting therapy for ovarian cancer through tumor tissue-specific delivery of miRNA-29b to reexpress PTEN tumor-suppressor gene. A chimera (Chi-29b) was constructed to compose of a mucin 1 (MUC1) aptamer targeting tumor cell surface MUC1 protein and miR-29b inhibiting DNA methyltransferases' expression, subsequently reexpressing PTEN gene. The specificity and efficacy of the chimera delivery were analyzed in OVCAR-3 ovarian tumor cells, and the biological activities of the chimera were identified by the expression of its downstream molecules and cell apoptosis. We demonstrated that Chi-29b chimera can be specifically delivered into OVCAR-3 cells in a concentration-dependent manner. Dicer efficiently cleaved the Chi-29b chimera to release miR-29b. Chi-29b chimera downregulated Dnmt1, Dnmt3a, and Dnmt3b protein levels; induced hypomethylation in PTEN promoter; and upregulated PTEN mRNA and protein expression in OVCAR-3 cells. Importantly, Chi-29b chimera significantly induced apoptosis in OVCAR-3 cells. Our study indicated that Chi-29b chimera can effectively exert antitumor effect through specific delivery of miR-29b into OVCAR-3 tumor cells, subsequently reexpressing PTEN gene and inducing cell apoptosis.

Citing Articles

Exosomes in diagnostic and therapeutic applications of ovarian cancer.

Bhavsar D, Raguraman R, Kim D, Ren X, Munshi A, Moore K J Ovarian Res. 2024; 17(1):113.

PMID: 38796525 PMC: 11127348. DOI: 10.1186/s13048-024-01417-0.

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.

Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P Cancers (Basel). 2023; 15(21).

PMID: 37958473 PMC: 10647731. DOI: 10.3390/cancers15215300.

The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.

Song K, Artibani M Health Sci Rep. 2023; 6(5):e1235.

PMID: 37123549 PMC: 10140645. DOI: 10.1002/hsr2.1235.

DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors.

Shishparenok A, Furman V, Zhdanov D Cancers (Basel). 2023; 15(7).

PMID: 37046816 PMC: 10093432. DOI: 10.3390/cancers15072151.

Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Kandettu A, Adiga D, Devi V, Suresh P, Chakrabarty S, Radhakrishnan R Genes Dis. 2022; 9(6):1443-1465.

PMID: 36157483 PMC: 9485269. DOI: 10.1016/j.gendis.2021.12.026.

References

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

Teoh D, Secord A . Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer. 2012; 22(3):348-59. DOI: 10.1097/IGC.0b013e31823c6efd. View

Slack F, Weidhaas J . MicroRNA in cancer prognosis. N Engl J Med. 2008; 359(25):2720-2. PMC: 10035200. DOI: 10.1056/NEJMe0808667. View

Constantinou P, Danysh B, Dharmaraj N, Carson D . Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab. 2011; 6(6):835-848. PMC: 3245640. DOI: 10.1586/eem.11.70. View

Willmott L, Fruehauf J . Targeted therapy in ovarian cancer. J Oncol. 2010; 2010:740472. PMC: 2814233. DOI: 10.1155/2010/740472. View

Zhu X, Li T, Peng S, Ma X, Chen X, Zhang X . Maternal deprivation-caused behavioral abnormalities in adult rats relate to a non-methylation-regulated D2 receptor levels in the nucleus accumbens. Behav Brain Res. 2010; 209(2):281-8. DOI: 10.1016/j.bbr.2010.02.005. View

Ni X, Zhang Y, Ribas J, Chowdhury W, Castanares M, Zhang Z . Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest. 2011; 121(6):2383-90. PMC: 3104752. DOI: 10.1172/JCI45109. View

Van Simaeys D, Lopez-Colon D, Sefah K, Sutphen R, Jimenez E, Tan W . Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX. PLoS One. 2010; 5(11):e13770. PMC: 2967474. DOI: 10.1371/journal.pone.0013770. View

Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T . Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2001; 60(24):7052-6. View

10.

McNamara 2nd J, Andrechek E, Wang Y, Viles K, Rempel R, Gilboa E . Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24(8):1005-15. DOI: 10.1038/nbt1223. View

11.

Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H . Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One. 2011; 6(9):e24077. PMC: 3164674. DOI: 10.1371/journal.pone.0024077. View

12.

Kinlough C, Poland P, Bruns J, Harkleroad K, Hughey R . MUC1 membrane trafficking is modulated by multiple interactions. J Biol Chem. 2004; 279(51):53071-7. DOI: 10.1074/jbc.M409360200. View

13.

Marsit C, Zheng S, Aldape K, Hinds P, Nelson H, Wiencke J . PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005; 36(7):768-76. DOI: 10.1016/j.humpath.2005.05.006. View

14.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

15.

Simon J, Lange C . Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008; 647(1-2):21-9. DOI: 10.1016/j.mrfmmm.2008.07.010. View

16.

Trasler J . Epigenetics in spermatogenesis. Mol Cell Endocrinol. 2009; 306(1-2):33-6. DOI: 10.1016/j.mce.2008.12.018. View

17.

Oliveira A, Ross J, Fletcher J . Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol. 2006; 124 Suppl:S16-28. DOI: 10.1309/5XW3L8LU445QWGQR. View

18.

Carracedo A, Alimonti A, Pandolfi P . PTEN level in tumor suppression: how much is too little?. Cancer Res. 2011; 71(3):629-33. PMC: 3249925. DOI: 10.1158/0008-5472.CAN-10-2488. View

19.

Collinson F, Seligmann J, Perren T . Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Curr Oncol Rep. 2012; 14(6):509-18. DOI: 10.1007/s11912-012-0274-4. View

20.

Lou Y, Yang X, Wang F, Cui Z, Huang Y . MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med. 2010; 26(6):819-27. DOI: 10.3892/ijmm_00000530. View